Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-09-15 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
第四届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the eighth meeting of the fourth board of directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to related announcements on the stock exchange website. The content focuses on board decisions such as adjustments to stock option exercise prices, stock option cancellations, nomination of a new director, and proposals for shareholder meetings. There is no financial data or comprehensive financial reporting. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 2687 characters, which is consistent with a detailed board meeting announcement rather than a full report or regulatory filing. Therefore, the appropriate classification is MANG with high confidence.
2025-09-15 Chinese
关于北京三元基因药业股份有限公司调整2022年股权激励计划预留授予部分股票期权行权价格、注销部分股票期权事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by Beijing Hylands Law Firm to Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding adjustments to the exercise price and cancellation of stock options under its 2022 equity incentive plan. It is not an earnings release, financial report, management change announcement, or other specific report; rather it is a compliance/legal opinion document prepared for regulatory submission and information disclosure. This type of law‐firm legal opinion does not fit the specialized categories and thus falls into the fallback “Regulatory Filings” category (RNS).
2025-09-15 Chinese
关于调整2022年股权激励计划预留授予部分股票期权行权价格的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the adjustment of the exercise price of reserved stock options under the 2022 equity incentive plan. It details the board and committee meetings, legal opinions, and the rationale for the adjustment following the completion of the 2023 dividend distribution. The content focuses on stock option plan adjustments, legal compliance, and disclosures related to equity incentives. There is no financial statement or comprehensive financial report included, nor is it a simple announcement of a report publication. The document is a regulatory announcement about changes in the equity incentive plan, specifically about stock option exercise price adjustments and related legal and board approvals. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is about stock option plan adjustments rather than new share issuance or capital structure changes.
2025-09-15 Chinese
2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 second extraordinary shareholders meeting of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals, and legal opinions confirming the legality and validity of the meeting and voting process. The content focuses on shareholder voting outcomes and governance matters rather than financial results or management commentary. The document is not a full annual or interim report, nor is it a presentation or earnings release. It is a formal declaration of voting results from a shareholders meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4035 characters, which is sufficient to contain detailed voting results rather than just a brief announcement or a report publication notice. Therefore, the classification is DVA with high confidence.
2025-09-15 Chinese
关于召开2025年第三次临时股东会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2025 third extraordinary general meeting of shareholders for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting date, voting methods (on-site and online), registration procedures, and the agenda item (nomination of a director). The document does not contain any financial statements, audit information, or detailed financial data. It is primarily an announcement about the meeting logistics and agenda, not the meeting materials or results themselves. The document length is under 5,000 characters and it serves as a formal meeting notice. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual General Meeting or other shareholder meetings.
2025-09-15 Chinese
对全资子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's capital increase investment into its wholly owned subsidiary. It details the investment amount, the decision-making process, and the impact on the company. It does not contain financial statements or detailed financial performance data. The document is relatively short (2154 characters) and serves as a formal disclosure of a financing activity (capital injection). This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2025-09-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.